- Company
- Global companies made KRW 21M per employee last year
- by An, Kyung-Jin Apr 23, 2020 06:26am
- Korea Otsuka Pharmaceutical has generated the highest operating profit per employee last year among Korean branches of multinational pharmaceutical companies. Each employee at the multinational company has made 108 million won worth of operating profit. On Apr. 21, an analysis on 30 multinational pharmaceutical companies in Korea surveyed
- Company
- COVID-19 hinders Italian API distribution causing stock-out
- by Jung, Hye-Jin Apr 22, 2020 06:03am
- Due to temporary suspension of active pharmaceutical ingredient (API) distribution amid COVID-19 pandemic, many drugs have been reportedly sold out. The industry experts see that the restricted international logistics of human and material resources during the pandemic has affected a number of drugs to be stocked out for a long and shor
- Company
- GSK Korea pays the highest average salary at KRW 136M
- by An, Kyung-Jin Apr 22, 2020 06:02am
- Among all Korean affiliates of multinational pharmaceutical companies, employees at GlaxoSmithKline (GSK) Korea have received the highest average salary of 136 million won. Employees working at Sanofi Pasteur, GSK Consumer Healthcare Korea, Galderma Korea, Allergan Korea, Boehringer Ingelheim Korea and AbbVie Korea have received average salary o
- Company
- Lipitor tops outpatient market again amid COVID-19
- by Chon, Seung-Hyun Apr 21, 2020 06:27am
- The 2019 novel coronavirus infection (COVID-19) seems to not have affected the top outpatient prescription drug rank in Korea. Dyslipidemia treatment Lipitor remained on the top of the leader board with a big gap. The prescription volumes of anticancer Tagrisso and cholesterol-lowering combination drug Rosuzet have also continued to skyrocket. B
- Company
- Bridion generic makers lose patent dispute after all
- by Kim, Jin-Gu Apr 20, 2020 06:34am
- Indicated for the reversal of neuromuscular blockade in people undergoing surgery, MSD’s Bridion (sugammadex) has successfully defended its patent rights. On Apr. 17, the Intellectual Property Trial and Appeal Board has ruled favorable for the original patentee MSD over a patent dispute with CTC BIO. A pharmaceutical market resear
- Company
- Half of multinational companies in Korea restructured 2019
- by An, Kyung-Jin Apr 20, 2020 06:30am
- Apparently, one out of two multinational pharmaceutical companies in Korea has downsized last year. The outcome contrasts with Korean pharmaceutical and bio companies that have increased employment in the same time, despite the worsened profitability. Analyzing audit reports submitted to the Financial Supervisory Service (FSS) on Apr. 16, 13
- Company
- Pfizer Korea Upjohn, last year's sales were ￦385.8 billion
- by Kim, Jin-Gu Apr 20, 2020 06:30am
- It was confirmed that the annual sales of Pfizer Korea Upjohn, which was split from Korea Pfizer Pharmaceuticals last year, amounted to ￦385.8 billion. Korea Pfizer Pharmaceuticals(￦395.7 billion) is not much different. Considering that Pfizer and the Pfizer Upjohn have a global sales ratio of 8 to 2, the sales share of Pfizer Upjohn in
- Company
- Twice-delayed amid COVID-19 Cancer Committee rescheduled
- by Eo, Yun-Ho Apr 17, 2020 06:22am
- The Cancer Deliberation Committee’s meeting, postponed twice already, has been rescheduled. The Korean pharmaceutical industry sources reported the Health Insurance Review and Assessment Service (HIRA) has decided to resume the Cancer Deliberation Committee’s talks on expanding anticancer treatment coverage on Apr. 29. Amid COVID-1
- Company
- Merck's retirement allowance of ￦9.3 billion last year
- by An, Kyung-Jin Apr 17, 2020 06:21am
- Merck KGaA spent nearly 10 billion won last year as employee severance pay. With the sale of two types of hypertension and diabetes treatments, retirement payments related to restructuring jumped four times from the previous year. According to Merck KGaA's audit report submitted to the Financial Supervisory Service on the 14th, last year,
- Company
- Multinational companies show significant gap in performance
- by An, Kyung-Jin Apr 17, 2020 06:21am
- Multinational pharmaceutical companies in Korea showed drastically polarized performance last year. Their revenue fluctuated depending on how well the emerging driving forces took over the position of now-off-patent blockbuster drugs. Most of the companies had a drop in operating profit, but companies like Alcon, AbbVie and Sanofi-Aventis have s
